Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016382 (flushing)
 6,387 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Treatment with the somatostatin analogue octreotide, SMS 201-995 (Sandostatin), has been carried out in a series of 23 patients with malignant midgut carcinoid tumours. The patients received initially 50 micrograms twice a day for six months, thereafter a median of 100 micrograms twice daily. Six of 22 evaluable patients (28%) showed objective tumour response lasting for 6 to 30 months. Stable disease was observed in 8 of the 22 patients (36%) and progressive disease in a further 8 patients (36%). A subjective response with decrease of diarrhoea or flushing was noted in 11 out of 22 patients (50%). Two out of 6 patients with objective response demonstrated a significant decrease of tumour size lasting for 6 and 30 months respectively. In order to maintain the clinical response, the dose had to be increased in all 6 responders. The adverse effects included development of diabetic blood glucose levels in 8 out of 22 patients (36%). Albumin-modified serum calcium levels were significantly reduced after treatment with octreotide 50 micrograms twice a day. One patient developed symptoms of hypocalcemia which was reversed by supplementation with calcium and D-vitamins. The somatostatin analogue SMS 201-995 has a beneficial effect in the treatment of patients with the carcinoid syndrome. However, the precise role of the drug in the long-term management of these patients has to be further investigated.
 ...
PMID:Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. 185 8

An improved CE-FA method using a polyelectrolyte multilayer (PEML) coated capillary is described. The coating was simply created by alternatively flushing the capillary with positively charged polyelectrolyte polybrene (HDB) and negatively charged polyelectrolyte dextran sulfate (DS). Human serum albumin (HSA) and 6 drugs were selected as an experimental model to evaluate such an improvement. The PEML coating was demonstrated to effectively reduce the protein adsorption on the capillary wall. Compared with the uncoated capillary, the repeatability (RSD%) of the EOF mobility and the plateau height of free drug were improved significantly from 3.7% to 0.51% and from 0.61% to 0.34%, respectively. No interference of the coating on the measurement of protein-drug binding parameters was observed.
 ...
PMID:Improved capillary electrophoresis frontal analysis by dynamically coating the capillary with polyelectrolyte multilayers. 2247 76